source
- Akeso and Summit report ivonescimab meets primary endpoint in China Phase 3 biliary tract cancer trialAkeso Therapeutics and partner Summit Therapeutics announced that their bispecific antibody ivonescimab achieved the primary efficacy endpoint in a Phase 3 study conducted exclusively in China. Th…
- FDA issues early alert on CooperSurgical infant nasal CPAP devices with loose tubing connectionThe FDA’s Center for Devices and Radiological Health has posted an Early Alert about a potential high-risk issue with certain CooperSurgical infant nasal CPAP devices. The problem involves a loose…